Bharat Book

Sarcomas - Pipeline Review, H2 2013

Press Release   •   Dec 09, 2013 11:02 IST

Dec 09, 2013 : Bharat Book Bureau presents the new report, on 'Sarcomas - Pipeline Review, H2 2013'  also reviews key players involved in the therapeutic development for Sarcomas. Sarcomas - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


- A snapshot of the global therapeutic scenario for Sarcomas.
- A review of the Sarcomas products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Sarcomas pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Sarcomas.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Sarcomas pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Companies Mentioned

Shionogi & Co., Ltd.
AstraZeneca PLC
Eli Lilly and Company
GlaxoSmithKline plc
Gamida Cell Ltd.
Eisai Co., Ltd.
Marshall Edwards, Inc.
Oncolytics Biotech Inc.
Pharmacyclics, Inc.
PCI Biotech AS
MabVax Therapeutics, Inc.
Morphotek, Inc.
Philogen S.p.A.
Neotropix, Inc.
Axelar AB
Polaris Group

Table of contents :

Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Sarcomas Overview 9
Therapeutics Development 10
An Overview of Pipeline Products for Sarcomas 10
Sarcomas Therapeutics under Development by Companies 12
Sarcomas Therapeutics under Investigation by Universities/Institutes 14
Late Stage Products 15
Comparative Analysis 15
Mid Clinical Stage Products 16
Comparative Analysis 16
Early Clinical Stage Products 17
Comparative Analysis 17
Discovery and Pre-Clinical Stage Products 18
Comparative Analysis 18
Sarcomas Therapeutics - Products under Development by Companies 19
Sarcomas Therapeutics - Products under Investigation by Universities/Institutes 20
Companies Involved in Sarcomas Therapeutics Development 21
Shionogi & Co., Ltd. 21
AstraZeneca PLC 22
Eli Lilly and Company 23
GlaxoSmithKline plc 24
Gamida Cell Ltd. 25
Eisai Co., Ltd. 26
Marshall Edwards, Inc. 27
Oncolytics Biotech Inc. 28
Pharmacyclics, Inc. 29
PCI Biotech AS 30
MabVax Therapeutics, Inc. 31
Morphotek, Inc. 32
Philogen S.p.A. 33
Neotropix, Inc. 34
Axelar AB 35
Polaris Group 36
Sarcomas - Therapeutics Assessment 37
Assessment by Monotherapy Products 37
Assessment by Combination Products 38
Assessment by Route of Administration 39
Assessment by Molecule Type 41
Drug Profiles 44
eribulin mesylate - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
eribulin mesylate - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
cixutumumab - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
MK-1775 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Fibromun - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
(amphinex + bleomycin sulfate) - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
NTX-010 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
AXL-1717 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
pracinostat - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
pelareorep - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
MORAb-004 - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
X-396 - Drug Profile 72

For more information kindly visit :

Related link :

About Bharat Book Bureau:

Bharat Book Bureau is the leading market research information provider for market research reports, , company profiles, industry analysis , country reports , business reports, newsletters and online databases Bharat Book Bureau provides over a million reports from more than 400 publishers around the globe. We cover sectors starting from Aeronautics to Zoology.

In case the reports don't match your requirement then we can do a specialized Custom Research for you. Our multifarious capabilities, cross-sector expertise and detailed knowledge of various markets, put us in a unique position to take up Custom Research demands of yourself.

Contact us at :

Bharat Book Bureau
Tel: +91 22 27810772 / 27810773
Toll Free No for USA/Canada : 1-866-279-8368
Follow us on twitter: 
Follow us on linked in : 
Our Blog : 

Bharat Book Bureau, the leading market research information aggregator provides market research reports, company profiles, country reports, newsletters, and online databases for the past twenty four years to corporate, consulting firms, academic institutions, government departments, agencies etc., globally, including India. Our market research reports help global companies to know different market before starting up business / expanding in different countries across the world.